Form 4: ANI Pharma HR Chief Boosts Stake with Restricted Stock

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, acquired 10,810 shares of common stock through a restricted stock award and disposed of 1,555 shares for tax purposes.

Summary

• Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, Inc. (ANIP), reported transactions involving the company's common stock.
• On February 26, 2026, Ms. Davis acquired 10,810 shares of common stock at a price of $77.15 per share as a restricted stock award.
• This restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• Following this acquisition, Ms. Davis's beneficial ownership increased to 60,073 shares.
• On February 28, 2026, Ms. Davis disposed of 1,555 shares of common stock at $73.90 per share.
• These shares were withheld for tax purposes in connection with the vesting of 3,040 previously reported restricted stock shares.
• After the disposition, Ms. Davis beneficially owns 58,518 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive is increasing their direct ownership in the company through a long-term incentive award, aligning their interests with shareholders.

Positives

• Krista Davis, SVP, Chief HR Officer, acquired 10,810 shares of common stock through a restricted stock award, increasing her direct ownership.
• The restricted stock award structure, vesting over four years, aligns management's long-term interests with shareholder value.

Negatives

• 1,555 shares were disposed of for tax withholding purposes, which is a common practice upon restricted stock vesting.

Future Outlook

The restricted stock award granted to Krista Davis is structured to vest in four equal annual installments, indicating a long-term incentive for management performance tied to the company's future success.

Industry Context

StockSavvy.ai notes that executive equity awards, particularly restricted stock, are a common practice in the pharmaceutical industry to align executive incentives with long-term shareholder value and retention. This type of compensation structure is prevalent across publicly traded companies, including peers like Pfizer or Merck, aiming to foster sustained growth and performance.

Comparison to Industry Standards

• The grant of restricted stock awards to senior executives like an SVP, Chief HR Officer, is a standard compensation practice across the pharmaceutical industry, comparable to companies such as Johnson & Johnson or Bristol Myers Squibb, which use similar long-term incentive plans to retain talent and align interests.
• The four-year vesting schedule for the restricted stock award is a common industry benchmark for executive equity compensation, promoting long-term commitment and performance, similar to vesting schedules observed at companies like Eli Lilly or Amgen.
• The disposition of shares for tax withholding upon vesting is a routine and expected event for equity compensation, consistent with practices at virtually all publicly traded companies offering restricted stock units or awards.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with long-term shareholder value due to the restricted stock award.
• Employees: Standard executive compensation practices may signal stability in leadership and compensation structures.

Next Steps

• Future vesting events for the restricted stock award on the first, second, third, and fourth anniversaries of February 26, 2026.

Key Dates

Recommendation

This Form 4 reports a standard executive compensation event involving restricted stock awards and subsequent tax-related dispositions. While the increase in executive ownership is generally positive for alignment, it does not present new fundamental information that would warrant a change in investment recommendation. The transactions are routine and expected, thus a "hold" recommendation is appropriate.

Keywords

ANI Pharmaceuticals, ANIP, Krista Davis, Form 4, Insider Trading, Restricted Stock, Equity Award, Executive Compensation, Stock Ownership